A Phase 2 Study of Belinostat (PXD101) in Patients with Relapsed or Refractory Acute Myloid Leukemia or Patients Over 60 with Newly-Diagnosed Acute Myloid Leukemia: A California Ca...

Por Kirschbaum, Mark H., Foon, Kenneth A., Frankel, Paul, Ruel, Christopher, Pulone, Bernadette, Tuscano, Joseph M., Newman, Edward M.
Publicado em 2014

A Phase 2 Study of Vorinostat for Treatment of Relapsed or Refractory Hodgkin Lymphoma: SWOG S0517

Por Kirschbaum, Mark H., Goldman, Bryan H., Zain, Jasmine M., Cook, James R., Rimsza, Lisa M., Forman, Stephen J., Fisher, Richard I.
Publicado em 2011

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and micro-RNA levels

Por Kretzner, Leo, Scuto, Anna, Dino, Pamela M., Kowolik, Claudia M., Wu, Jun, Ventura, Patrick, Jove, Richard, Forman, Stephen J., Yen, Yun, Kirschbaum, Mark H.
Publicado em 2011

A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide Against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study

Por Kirschbaum, Mark H., Frankel, Paul, Synold, Timothy W., Xie, Zhiliang, Yen, Yun, Popplewell, Leslie, Chen, Robert, Aljitawi, Omar S., Tuscano, Joseph M., Chan, Kenneth K., Newman, Edward M.
Publicado no Leuk Lymphoma (2016)

Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

Por Erba, Harry P., Othus, Megan, Walter, Roland B., Kirschbaum, Mark H., Tallman, Martin S., Larson, Richard A., Slovak, Marilyn L., Kopecky, Kenneth J., Gundacker, Holly M., Appelbaum, Frederick R.
Publicado no Leuk Res (2013)

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Por Piekarz, Richard L., Frye, Robin, Prince, H. Miles, Kirschbaum, Mark H., Zain, Jasmine, Allen, Steven L., Jaffe, Elaine S., Ling, Alexander, Turner, Maria, Peer, Cody J., Figg, William D., Steinberg, Seth M., Smith, Sonali, Joske, David, Lewis, Ian, Hutchins, Laura, Craig, Michael, Fojo, A. Tito, Wright, John J., Bates, Susan E.
Publicado em 2011

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Por Piekarz, Richard L., Frye, Robin, Turner, Maria, Wright, John J., Allen, Steven L., Kirschbaum, Mark H., Zain, Jasmine, Prince, H. Miles, Leonard, John P., Geskin, Larisa J., Reeder, Craig, Joske, David, Figg, William D., Gardner, Erin R., Steinberg, Seth M., Jaffe, Elaine S., Stetler-Stevenson, Maryalice, Lade, Stephen, Fojo, A. Tito, Bates, Susan E.
Publicado em 2009

Phase II Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial

Por Jain, Nitin, Curran, Emily, Iyengar, Neil M., Diaz-Flores, Ernesto, Kunnavakkam, Rangesh, Popplewell, Leslie, Kirschbaum, Mark H., Karrison, Theodore, Erba, Harry P., Green, Margaret, Poire, Xavier, Koval, Greg, Shannon, Kevin, Reddy, Poluru L., Joseph, Loren, Atallah, Ehab L., Dy, Philip, Thomas, Sachdev P., Smith, Scott E., Doyle, L. Austin, Stadler, Walter M., Larson, Richard A., Stock, Wendy, Odenike, Olatoyosi
Publicado no Clin Cancer Res (2013)

Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications from Clinical and Correlative Data

Por Bates, Susan E., Eisch, Robin, Ling, Alex, Rosing, Douglas, Turner, Maria, Pittaluga, Stefania, Prince, H. Miles, Kirschbaum, Mark H., Allen, Steven L., Zain, Jasmine, Geskin, Larisa J., Joske, David, Popplewell, Leslie, Cowen, Edward W., Jaffe, Elaine S., Nichols, Jean, Kennedy, Sally, Steinberg, Seth M., Liewehr, David J., Showe, Louise C., Steakley, Caryn, Wright, John, Fojo, Tito, Litman, Thomas, Piekarz, Richard L.
Publicado no Br J Haematol (2015)